Critical Contrast: Coherus Biosciences (CHRS) versus Cidara Therapeutics (CDTX)

Coherus Biosciences (NASDAQ: CHRS) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings and analyst recommendations.

Insider and Institutional Ownership

82.5% of Coherus Biosciences shares are owned by institutional investors. Comparatively, 59.5% of Cidara Therapeutics shares are owned by institutional investors. 26.3% of Coherus Biosciences shares are owned by insiders. Comparatively, 18.9% of Cidara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Coherus Biosciences and Cidara Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Coherus Biosciences $190.11 million 3.01 -$127.33 million ($5.42) -1.76
Cidara Therapeutics N/A N/A -$48.16 million ($3.39) -2.05

Cidara Therapeutics has lower revenue, but higher earnings than Coherus Biosciences. Cidara Therapeutics is trading at a lower price-to-earnings ratio than Coherus Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings for Coherus Biosciences and Cidara Therapeutics, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coherus Biosciences 0 0 8 0 3.00
Cidara Therapeutics 0 1 7 1 3.00

Coherus Biosciences presently has a consensus target price of $32.00, indicating a potential upside of 235.08%. Cidara Therapeutics has a consensus target price of $13.50, indicating a potential upside of 94.24%. Given Coherus Biosciences’ higher possible upside, equities analysts plainly believe Coherus Biosciences is more favorable than Cidara Therapeutics.


This table compares Coherus Biosciences and Cidara Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Coherus Biosciences -73.89% -582.31% -138.04%
Cidara Therapeutics N/A -82.17% -65.11%

About Coherus Biosciences

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company’s product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.

About Cidara Therapeutics

Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. The Company is also developing CD201, its bispecific antimicrobial immunotherapy.

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with's FREE daily email newsletter.

Leave a Reply